Columbia, MONCT06947304Now EnrollingIRB Ready

Nonalcoholic Steatohepatitis (NASH) Clinical Trial in Columbia, MO

Access cutting-edge nonalcoholic steatohepatitis (nash) treatment through this clinical trial at a research site in Columbia. Study-provided care at no cost to qualified participants.

Sponsored by Corcept Therapeutics

Quick Self-Assessment

See if you qualify for this Columbia location

Preparing your pre-screening questions…

Expert Care in Columbia

Access nonalcoholic steatohepatitis (nash) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related nonalcoholic steatohepatitis (nash) treatment provided free

Apply for This Columbia Location

Check if you qualify for this nonalcoholic steatohepatitis (nash) clinical trial in Columbia, MO

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Columbia

    Convenient for MO residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Columbia site if eligible
  4. 4Begin participation

About This Nonalcoholic Steatohepatitis (NASH) Study in Columbia

A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Sponsor: Corcept Therapeutics

Who Can Participate

Inclusion Criteria

AST \> 17 U/L for women and AST \> 20 U/L for men. The AST inclusion criterion does not apply to participants with an eligible historical liver biopsy performed within 12 months of screening showing one of the following:
NAFLD Activity Score (NAS) ≥ 4 (with at least 1 point in each subcomponent of steatosis, inflammation, and ballooning) and NASH Clinical Research Network (CRN) fibrosis score of F0 OR
NAS ≥ 3 (with at least 1 point in each subcomponent of steatosis, inflammation, and ballooning) and NASH CRN fibrosis score of F1 OR
NAS ≥ 2 (with at least 1 point in subcomponent of ballooning or inflammation) and a NASH CRN fibrosis score of F2-3
MRI-PDFF with ≥ 8% steatosis; this assessment must be performed within 4 weeks of the Baseline Visit.
Presence of at least 1 of the following metabolic syndrome characteristics that increase the risk of MASH: a. Diagnosis of type 2 diabetes managed with diet alone or diet and metformin (metformin dose must be stable for at least 1 month prior to screening) OR b. Presence of 3 or more components of metabolic syndrome: i. Fasting blood glucose ≥ 100 mg/dL (5.6 mmol/L) or treatment for elevated blood glucose with metformin ii. Systolic blood pressure ≥ 130 mm Hg, diastolic blood pressure ≥ 85 mm Hg, or treatment for hypertension iii. Serum TG ≥ 150 mg/dL (1.7 mmol/L) iv. Serum high-density lipoprotein cholesterol (HDL) \< 40 mg/dL (1 mmol/L) in men and \< 50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL v. Having overweight or obesity (body mass index \[BMI\] ≥ 25 kg/m2 \[BMI
23 kg/m2 in Asians\]), or increased waist circumference ≥ 102 cm (40 in) in men and ≥ 88 cm (35 in) in women (men ≥ 90 cm \[35.4 in\]; women ≥ 80 cm \[31.5 in\] in Asians). Other inclusion criteria may apply

Exclusion Criteria

Participation in another clinical trial for MASH or weight loss (e.g., GLP-1 receptor agonists) within the last 3 months.
Participation in any other clinical trial within the last 3 months or 5 half-lives of the treatment, whichever is longer.
Women who are pregnant, planning to become pregnant, or lactating.
BMI \< 18 kg/m² or \> 45 kg/m².
Significant alcohol consumption exceeding 20 g/day for women or 30 g/day for men within 1 year prior to screening.
Positive urine drug screen for amphetamines, cocaine, opiates, or cannabinoids.
Known or suspected cirrhosis or signs of hepatic decompensation.
Other chronic liver diseases such as hepatitis B or C, autoimmune hepatitis, primary biliary cholangitis, or Wilson's disease.
History of myocardial infarction, unstable angina, or stroke within 3 months prior to screening.
Uncontrolled hypertension (systolic \> 160 mm Hg or diastolic \> 100 mm Hg).
Current use of medications prohibited due to potential drug-drug interactions with study treatment.
Contraindications to magnetic resonance imaging (MRI). Other exclusion criteria may apply

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Columbia?

Yes, this clinical trial (NCT06947304) has an active research site in Columbia, MO that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Nonalcoholic Steatohepatitis (NASH) Treatment Options in Columbia, MO

If you're searching for nonalcoholic steatohepatitis (nash) treatment options in Columbia, MO, this clinical trial (NCT06947304) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Columbia research site is actively enrolling participants for this clinical trial. You'll receive care from experienced nonalcoholic steatohepatitis (nash) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all nonalcoholic steatohepatitis (nash) clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Columbia, MO

See all ankylosing spondylitis clinical trials recruiting in Columbia — not just this study.

Browse Ankylosing Spondylitis Trials in Columbia →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsNASH TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Columbia?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Columbia, MO